CDC Logo Tuberculosis Information CD-ROM   Image of people
     
jump over main navigation bar to content area
Home
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Newsletters
Ordering Information
Help

 

U.S. Department of Health and Human Services

  

TB Guidelines

2000

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection -  MMWR 2000; 49 (No. RR-6)
www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm
PDF
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - MMWR 2003; 52 (No. 31). www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm PDF
Updated Guidelines for the Use of Rifabutin or Rifampin for the Treatment and Prevention of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors - MMWR 2000;  49 (No. 9)
www.cdc.gov/mmwr/preview/mmwrhtml/mm4909a4.htm
PDF

 

 

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333